Article abstract-Background: Studies examining the brains of individuals with autism have identified anatomic and pathologic changes in regions such as the cerebellum and hippocampus. Little, if anything, is known, however, about the molecules that are involved in the pathogenesis of this disorder. Objective: To identify genes with abnormal expression levels in the cerebella of subjects with autism. Methods: Brain samples from a total of 10 individuals with autism and 23 matched controls were collected, mainly from the cerebellum. Two cDNA microarray technologies were used to identify genes that were significantly up-or downregulated in autism. The abnormal mRNA or protein levels of several genes identified by microarray analysis were investigated using PCR with reverse transcription and Western blotting. ␣-Amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA)-and NMDA-type glutamate receptor densities were examined with receptor autoradiography in the cerebellum, caudate-putamen, and prefrontal cortex. Results: The mRNA levels of several genes were significantly increased in autism, including excitatory amino acid transporter 1 and glutamate receptor AMPA 1, two members of the glutamate system. Abnormalities in the protein or mRNA levels of several additional molecules in the glutamate system were identified on further analysis, including glutamate receptor binding proteins. AMPA-type glutamate receptor density was decreased in the cerebellum of individuals with autism (p Ͻ 0.05). Conclusions: Subjects with autism may have specific abnormalities in the AMPA-type glutamate receptors and glutamate transporters in the cerebellum. These abnormalities may be directly involved in the pathogenesis of the disorder.
1 autism remains an enigmatic, pervasive developmental disorder. The lifelong syndrome is characterized by three major symptoms: deficits in social interaction, language abnormalities, and stereotyped repetitive patterns of behavior. 2 Additional characteristics of the disorder are that three to four times more men are affected than women 3 and by adulthood about onethird will have had at least two unprovoked seizures. 4 The prevalence of autism is generally considered to be two to five in 10,000. 3 A recent study, however, suggests autism may be considerably more common, with a prevalence greater than one in 1000. 3 Autism, a behaviorally defined disorder, is the consequence of a variety of genetic and nongenetic causes. Although it is therefore difficult to determine the primary cause of autism, there has been a growing interest in identifying common pathways that are affected as a result of the disorder. Autism is thought to reflect a nonprogressive brain impairment; however, only a few studies have examined alterations in postmortem brain from affected individuals. Neuropathologic studies have detected abnormalities in regions including the brainstem, hippocampus, and other diencephalic structures. 5 Thus far, the most consistent findings are the abnormalities found in the cerebella of persons with autism, which is the region we chose to examine in this study. A 35 to 50% reduction in the number of Purkinje cells in autism cerebellum when compared with normal cerebellum has been demonstrated. [5] [6] [7] Several MRI studies suggest that the cerebellum may be smaller in individuals with autism. 8, 9 Apart from neuroanatomic evidence of brain abnormalities, we know little, if anything, about brain disturbances at the molecular level, perhaps because of the limited availability of postmortem brain samples from individuals with autism.
In seeking to understand the molecular pathophysiology of autism in brain, cDNA microarray technology represents an efficient way to screen thousands of genes at once for expression differences. 10, 11 This approach may be useful in identifying cellular pathways that have been perturbed as a result of autism and in discovering genes that serve as diagnostic markers. Most human studies using cDNA microarrays have focused on cell lines or tumors. However, high-density microarrays also provide a useful tool for the study of brain tissue, including diseases such as autism, in which neuronal cell lines or animal models are not available. 12 Studies have used microarrays to measure gene expression in brain samples from patients with neurologic disorders such as MS 13 and AD. 14 In this study, cDNA microarrays are used to examine global changes in gene expression in the postmortem cerebella of individuals with autism, a region with known pathology.
Materials and methods. Tissue samples.
Frozen postmortem brain samples from the cerebellar cortex of nine autistic (A1 to A5; A7 to A10) and 18 control subjects (C1 to C9; C11 to C19) were obtained from the Harvard Brain Tissue Resource Center (Belmont, MA), with the support of the Autism Research Foundation (Boston, MA) and the University of Maryland Brain and Tissue Bank (Baltimore, MD). Most of these samples were from the cerebellum; however, several samples from the prefrontal cortex and caudate-putamen were also provided (table 1). The diagnosis of autism was assigned by a neurologist based on Diagnostic and Statistical Manual-IV criteria 15 and, in five of the nine cases, the Autism Diagnostic Interview-Revised. 16 Additional frozen samples from the cerebellar cortex of one autistic (A6) and one control subject (C10) were obtained from the University of Miami (Miami, FL) in conjunction with the Maryland Brain and Tissue Bank. The diagnosis of autism was assigned by a neurologist based on the Childhood Autism Rating Scale. 17 An additional four control postmortem brain samples (C20 to C23) from the prefrontal cortex or caudate-putamen were provided by the Maryland Brain and Tissue Bank. Of the 10 subjects with autism examined in this study, four (A1, A2, A4, and A10) had a history of seizures, whereas the other cases had no history of seizures (A3, A5, A7 to A9) or information was unavailable (A6). Additional clinical data for the patients with autism, including cause of death, IQ, and medication status prior to death are provided (see table 1 , supplementary content). The mean age (Ϯ SD) of all 10 patients with autism was 19 years (Ϯ 14 years), and the mean age (Ϯ SD) of the 23 control subjects was 22 years (Ϯ 15 years). Autism and control groups were matched for age, gender, and postmortem interval (PMI) within each experiment.
Autism and control cerebellum samples (~250 mg) were prepared for protein analysis by homogenizing in SHEEP buffer (0.32 M sucrose, 4 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid]), 0.1 mM egtazic acid, 0.1 mM ethylenediaminetetra-acetic acid, and 0.3 mM phenylmethane sulfonylfluoride). This preparation was then centrifuged at 2000 ϫ g for 10 minutes at 4°C. The supernatant was collected and protein concentrations were determined by a protein assay, 18 using bovine serum albumin as a standard. All tissue homogenates had a pH Ͼ6.3, which has been shown to be optimal for mRNA preservation in human postmortem brain. 19 Total RNA from each brain sample was isolated using TRIzol (Gibco-BRL, Gaithersburg, MD). RNA yield was determined by measuring the absorbance. The A 260 /A 280 ratio for each sample was confirmed to be between 1.9 and 2.0, the ratio of pure RNA (data not shown). Integrity of RNA was also assessed by electrophoresing samples on an ethidium bromidestained, denaturing agarose gel (data not shown).
cDNA array hybridization and analysis. Gene expression was analyzed using the Atlas Human Neurobiology array (Clontech Laboratories, Palo Alto, CA), which consists of 588 human cDNA spotted in duplicate onto a nylon membrane. A total of eight individual hybridizations were performed with autism (A1, A2, A4, A9) and control (C7 to C9, C11) cerebellum samples. Fifteen micrograms of total RNA from each sample were used to isolate poly A ϩ RNA and synthesize radiolabeled cDNA probes as directed by the manufacturer. Hybridization intensity of labeled prod- Gene expression was also evaluated with the UniGEM V2 array (Incyte Genomics, Palo Alto, CA), which contains 9374 sequence-verified cDNA immobilized on a glass slide. One hundred micrograms of total RNA from nine autism (A1 to A6, A8 to A10) and from a pool of four control (C7 to C9, C11) cerebellum samples were sent as coded samples to Incyte Genomics, where poly A ϩ was isolated and cDNA probes synthesized with the fluorescent markers Cy3 (autism) and Cy5 (control pool). Equal amounts of poly A ϩ were used to generate probes. Nine hybridizations were performed, one for each autism sample against the control pool. For each array, Incyte Genomics measured the intensity values for each cDNA signal and also globally normalized the Cy5 signal to the Cy3 signal. To be included in the analysis of an array, signals were at least 2.5-fold above background level and constituted at least 40% of the defined signal area. If a gene did not meet these criteria in more than three of the nine arrays, the gene was excluded from further analysis. Internal array controls were not included in the analysis of microarray data. To calculate fold regulation of a gene, a ratio of autism signal intensity to normalized control pool signal intensity was calculated for each array. These ratios were then averaged across the nine experiments. Finally, fold regulation was calculated based on whether the gene was up-(average ratio) or downregulated (Ϫ[1/average ratio]) in autism samples.
Reverse transcriptase PCR. First strand cDNA was synthesized from total RNA using oligo d(T) with Superscript II reverse transcriptase as directed by the manufacturer (Life Technologies, Rockville, MD). Approximately 20 ng of cDNA were added to a 100-L PCR mix containing 1.5 mM of MgCl 2 , 200 M of each nucleotide, 2.5 units of Taq DNA polymerase (Qiagen, Valencia, CA), and 0.5 M of each gene-specific primer. Glyceraldehyde-3-phosphate dehydrogenase was used as a control to normalize gene expression. The primer sequences that were used for PCR are provided (table 2, supplementary content). The reaction mixtures were subjected to 24 cycles of two-step PCR (Clontech). Each cycle consisted of 20 seconds at 94°C and 1 minute at 70°C. The entire program was followed by a 5-minute extension period at 68°C. The reactions were subjected to an additional successive three cycles and viewed on an ethidium bromide-stained agarose gel to determine when the amplification of each product was within the I ϭ Incyte Genomics UniGEM V2 array, mean of nine autistic/control comparisons; C ϭ Clontech Atlas Human Neurobiology array, mean of four autistic/ control comparisons, fold regulation; GABA ϭ ␥-aminobutyric acid; EST ϭ expressed sequence tag; TU3A ϭ downregulated in renal cell carcinoma; MITF ϭ microphthalmia-associated transcription factor; EAAT 1 ϭ excitatory amino acid transporter 1; GFAP ϭ glial fibrillary acidic protein; RAP-1A ϭ ras-related protein 1A; SPS2 ϭ selenophosphate synthetase 2; ALAS 1 ϭ 5-aminolevulinate synthase 1.
linear phase. Bands in the linear phase were quantified by measuring mean density using NIH image analysis software (NIH, Bethesda, MD). The ratio of the gene band density to the density of its glyceraldehyde-3-phosphate dehydrogenase band was calculated for each sample. A paired t-test was performed to evaluate differences in gene expression between control and autism groups. To assess whether the differences between autism and control groups varied as a function of age or PMI, multiple regression analysis was performed. Subtractive hybridization and southern blotting. The Micro-FastTrack isolation kit (Invitrogen, Carlsbad, CA) was used to purify poly A ϩ RNA from a pool of total RNA (100 g) from four autism (A1, A2, A4, A9) and three control (C7 to C9) cerebellum samples. Poly A ϩ RNA was reversed transcribed to cDNA, digested with RsaI, and subtracted using PCR-Select cDNA Subtraction kit (Clontech). Pools of differentially expressed cDNA were subcloned into a TA-cloning vector (Invitrogen) and sequenced. The identity of band 4.1N (KIAA0338; Genbank accession number XM_047295) was determined by Basic Local Alignment Search Tool searching with Ͼ99% nucleotide identity over a region of at least 100 base pairs used as a criterion. The sequence of band 4.1N identified in subtraction spanned base pairs 3726 to 4122 (GenBank identifier: AB002336). The band 4.1N clone isolated from subtraction was random prime labeled with Rediprime II (Amersham Pharmacia Biotech, Arlington Heights, IL) using [
32 P]deoxycytidine triphosphate. This probe was then hybridized to a nylon membrane containing pools of upand downregulated cDNAs generated by subtractive hybridization.
Western blotting. Twenty micrograms of each cerebellum sample were loaded onto a 4 to 15% sodium dodecyl sulfate polyacrylamide gradient gel (Bio-Rad, Hercules, CA) and electrophoresed at 60 mA for 90 minutes. A reference sample was electrophoresed on every gel so that individual gels could be compared. Proteins were transferred to Protran nitrocellulose membranes (Schleicher & Schuell, Keene, NH) in tromethamine/glycine buffer (2.5 mM tromethamine, 192 mM glycine, 20% methanol) overnight at 30 mA. Nonspecific binding sites were blocked for 1 hour at room temperature in 50 mM of tromethamine buffer containing 150 mM of NaCl and 0.1% polysorbate 20 with 5% nonfat dry milk. Immunostaining was performed by incubating the primary antibody for 1 hour at room temperature and was followed by horseradish peroxidase-conjugated secondary for 1 hour at room temperature. Signal was detected with an enhanced chemiluminescence detection system. Bands were quantified by measuring mean density using NIH image analysis software. To standardize protein levels, the Western blots were reprobed with an actin antibody. The ratio of the sample's protein band intensity to its actin band intensity was calculated. To evaluate differences between autism and control samples, t-tests were performed. To assess whether the differences between autism and control groups varied as a function of age or PMI, multiple regression analysis was performed.
mAb339, a mouse anti-␥-aminobutyric acid (GABA) A receptor ␣ chain monoclonal, and AB1504, a rabbit antiglutamate receptor 1 polyclonal, were used at a dilution of 1:50 (Chemicon International, Temecula, CA). A2066, a rabbit antiactin polyclonal (Sigma Chemical, St. Louis, MO), was used at a dilution of 1:500 and a mouse antineuron-specific enolase (NSE) polyclonal was used at a dilution of 1:100 (Calbiochem, San Diego, CA). Rabbit anti-excitatory amino acid transporter 1 (EAAT 1) and anti-EAAT 2 antibodies were kindly provided by Dr. Jeffrey Rothstein. Rabbit polyclonal antibodies against metabotropic glutamate receptor 2/3 (AB1553; 1:100), NMDA receptor 1 (AB1516; 1:100), and glutamate decarboxylase 1/2 (AB1511; 1:500) were purchased from Chemicon International. The rabbit antiband 4.1N antibody was supplied by Dr. Solomon Snyder. The rabbit anti-␣-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor 2/3, rabbit antiglutamate receptor interacting protein (GRIP), and rabbit antibodies against postsynaptic density protein 95 (PSD-95) were generously supplied by Dr. Richard Huganir. Horseradish peroxidase-labeled goat antimouse secondary and goat antirabbit secondary (Jackson Immunoresearch Laboratories, West Grove, PA) were used at a dilution of 1:5000.
Receptor autoradiography. Glutamate receptor density was evaluated in the cerebellum (A1, A3 to A7; C1 to C3, C5 to C10), prefrontal cortex (A1, A2, A4, A9; C6, C8, C19 to C23), and caudate-putamen (A1, A2, A4; C9, C17, C18, C21 to 23) of autism and control postmortem brain tissue. Frozen brain samples were cut serially (20 m thick) on a cryostat and then thaw-mounted onto Superfrost Pluscoated glass slides (VWR, West Chester, PA). Sections were processed for binding to AMPA and NMDA receptors as described previously. 20 Receptor densities were measured using a video-based image analysis system (Imaging Research, St. Catherines, Ontario). For each section, the densities of 25 small regions within the area of interest were averaged. The mean background was subtracted from this value. The average densities from four to eight separate sections from the same brain sample were then averaged. The statistical package S-PLUS 2000 (Insightful Corp., Seattle, WA) was used to perform t-tests and multiple regression analysis for each receptor type to determine whether receptor density differences between autism and control samples varied as a function of age or PMI.
Results. Expression profiling using cDNA microarrays. Two commercially available cDNA microarray technologies were used to identify differences in gene expression between autism and control postmortem cerebellum. Radiolabeled cDNA probes from four autism and four matched control samples were hybridized onto individual Atlas Neurobiology arrays (n ϭ 8 arrays). Of 588 cDNA on the array, 357 gave hybridization signals that were above background on every array. Onto the UniGEM V2 array, fluorescently labeled probes from nine autism samples were each hybridized simultaneously against probes generated from the same control pool (n ϭ 9 arrays). Of the 9374 cDNA, 8977 gave hybridization signals that were above background and met area criteria (see "Methods") in at least six of the nine arrays. For each array technology, the top up-and downregulated genes in autism are shown in table 2. Fewer genes are listed from the Atlas Neurobiology array as the array contained far fewer genes than the UniGEM V2 array. Gene expression results were generally consistent between the two array technologies (see table 2 ). A few of the genes, such as GABA A receptor ␣5, lie within autism susceptibility loci that genome screens have identified. 21 Differences in gene expression between the two clinical groups can be visualized by constructing a scatterplot of autism intensity versus control intensity (figure 1). Each point in the scatterplot represents one of the genes on the array. The majority of genes were expressed at the same level in both autism and control cerebellum and therefore lie on or near the line that bisects the data. Genes that are upregulated in autism lie above the line, whereas genes that are downregulated in autism lie below the line. Several genes that are significantly up-or downregulated in autism (see table 2) are labeled in the scatterplots. Although mean autism and control intensities were used for the Atlas Neurobiology array scatterplot, intensity values from a representative UniGEM V2 array were used, as intensity values cannot be averaged across arrays using this technology. The expressed sequence tag (EST), which is labeled with an asterisk in the UniGEM V2 scatterplot (see figure 1B) , is highly downregulated in this array experiment; however, on average it is not downregulated across all nine experiments. The mRNA levels of genes that were the focus of this study were consistently increased in autism cerebellum. Figure 1 shows the fold regulation in all four (Atlas Neurobiology array; see figure 1A , right) or all nine (UniGEM V2 array; see figure 1B, right) array experiments. Histograms of all the ratios from all array experiments were constructed to confirm that the data were normally distributed (data not shown). The average ratio Ϯ SD, calculated using fold regulations from all nine UniGEM V2 arrays, was 1.04 Ϯ 0.09 and for all four Atlas Neurobiology comparisons was 1.02 Ϯ 0.15.
Reverse transcriptase PCR confirmation. Reverse transcriptase PCR was used to confirm the differential expression of genes identified by the cDNA microarray analysis. Ten samples from the cerebella of subjects with autism and 10 matched controls were analyzed. Genes were chosen for RT-PCR from 1) the most up-and downregulated genes in table 2, 2) genes that showed consistent up-or downregulation on both the Atlas Neurobiology and Uni-GEM V2 arrays, and 3) genes that have a strong rationale for being involved in the pathogenesis of autism. Increases in the mRNA levels of several genes in autism were confirmed using RT-PCR (figure 2A upregulated gene in autism on the Atlas Neurobiology array. RT-PCR also demonstrated that EAAT 1 mRNA was increased in autism (p Ͻ 0.05). Glial fibrillary acidic protein (GFAP) and glutamate receptor AMPA 1 (GluR1) were additional genes that the Atlas Neurobiology array demonstrated were upregulated in the cerebella of subjects with autism. Levels of GFAP and GluR1 mRNA, assayed by RT-PCR, were increased in the cerebellum samples of the autism group (p Ͻ 0.002 and p Ͻ 0.05).
GABA A receptor ␣5 and clusterin were among the most upregulated genes on the UniGEM V2 array and also had greater mRNA amounts in autism when assayed by RT-PCR (p Ͻ 0.01). The C8 control sample in the GABA A receptor RT-PCR (see figure 2A, dagger) was eliminated from the statistical analysis of this gene because it was determined to be an outlier. An EST (GenBank identifier: AA94611) was one of the top 10 upregulated genes on the UniGEM V2 array. This gene is of interest because it lies within one of the autism susceptibility loci, 15q. 21 In addition, its transcript level, determined by RT-PCR, was increased in the cerebella of individuals with autism (p Ͻ 0.005). Although glycoprotein M6b was not among the top regulated genes, both array technologies consistently showed that glycoprotein M6b mRNA was increased in autism. This increase was confirmed by RT-PCR (p Ͻ 0.05). This gene may also warrant further study because it lies on the X chromosome, a chromosome that has been hypothesized to contain a defect in autism due to the greater number of men with the disorder. 3 Multiple regression analyses determined that none of the differences in mRNA levels between clinical groups were a function of age or PMI.
Transcript levels of several other genes were examined by RT-PCR, including chemokine receptor 1, apoE, KIAA0321, heat shock 70-kd protein 1, protease nexin 1, 5-aminolevulinate synthase 1, and acetylcholinesterase. However, no significant differences in the mRNA levels between autism and control samples were detected (data not shown).
mRNA levels of glutamate-related genes. Significantly higher levels of GluR1 and EAAT 1 mRNA in postmortem autism cerebellum were identified by microarray analysis 
05). (B) Investigation of mRNA levels of additional glutamaterelated genes. Excitatory amino acid transporter 2 (EAAT 2) and the AMPAtype glutamate receptors 2 and 3 have increased mRNA levels in autism (*p Ͻ 0.05). Glyceraldehyde-3-phosphate dehydrogenase band intensity (right, lower panel) was used for normalization of cDNA product in each sample. †Expressed sequence tag (EST) with GenBank identifier AA94611. GABA ϭ ␥-aminobutyric acid.
and confirmed with RT-PCR. Therefore, the mRNA levels of several other glutamate receptors and glutamate transporters were examined in autism. The same samples from the cerebellum of 10 subjects with autism and 10 control subjects were compared. The mRNA levels of two AMPAtype glutamate receptors, GluR2 and GluR3, were increased in cerebellum samples from individuals with autism (p Ͻ 0.002 and p Ͻ 0.03; see figure 2B ). However, other glutamate receptor types such as kainate 1, metabotropic 3, and NMDA 1 displayed no significant difference in their expression levels (data not shown). The mRNA of a glutamate transporter, EAAT 2, was increased (p Ͻ 0.02) in samples from persons with autism. Multiple regression analysis demonstrated that none of the significant mRNA differences between autism and control groups were a function of age or PMI. Members of other neurotransmitter systems were also examined in the same cerebellum samples using RT-PCR. However, no significant differences in the mRNA levels of dopamine receptor 2, neuropeptide Y6 receptor, cholinergic receptor beta 1, purinergic receptor P2X 4, purinergic receptor P2Y1, adenosine A2b receptor, GABA A receptors ␣2, ␤3, and ␥3, the GABA transporter, or the GABA synthesizing enzyme glutamate decarboxylase 1 were found between autism and control cerebellum (data not shown).
Subtractive hybridization. In a complementary approach to microarray analysis, we performed subtractive hybridization to identify mRNA transcripts that were differentially regulated in the cerebellum of individuals with autism. Band 4.1N (KIAA0338; GenBank identifier: AB002336) was one of the 40 cDNA clones that were isolated. A complete analysis of the additional sequences can be found elsewhere (Jeon and Pevsner, in preparation). Band 4.1N is a neuronal protein that binds to the C terminus of GluR1 and may link it to the actin cytoskeleton. 22 Subtraction identified this sequence as one that was upregulated in autism cerebellum compared with control cerebellum. Southern blotting was used to confirm the presence of this transcript in the upregulated pool of cDNA (data not shown).
Analysis of protein levels. Although levels of mRNA do not necessarily correspond to protein levels, it is of interest to determine whether the mRNA differences found in autism are also apparent at the protein level. The protein levels of these gene products were then examined by Western blotting (figure 3). Nine autism and 11 age-and gender-matched control postmortem cerebellum samples were analyzed.
The protein of the glial glutamate transporter EAAT 1, which appears as a doublet at approximately 60 kd, was increased threefold in autism cerebellum samples compared with controls (p Ͻ 0.001; see figure 3A ). Because seizures are present in about 33% of individuals with autism, 4 it may be that this increase is a compensatory mechanism that functions to decrease glutamate excitation. Reviewing the four subjects with a history of seizures (A1, A2, A4, A10), however, samples A2 and A1 exhibit relatively low EAAT 1 protein levels compared with other autism samples. Sample A4 does indeed show high levels of EAAT 1 protein, whereas sample A10 was not examined. Glutamate receptor AMPA 1 protein, also part of the glutamate system, is increased on average in autism cerebellum samples 2.5-fold (p Ͻ 0.0001). This may reflect a general disturbance in the glutamate system as a consequence of autism. Multiple regression analyses demonstrated that the increases in GluR1 and EAAT 1 protein were not a function of age or PMI. Using an antibody specific to the ␣ chain of the GABA A receptor, Western blotting demonstrated that levels of this protein were increased, although not significantly (data not shown). This particular antibody broadly recognized all ␣ subunits and was not specific for the ␣5 subunit. A potential upregulation of the ␣5 subunit protein could be masked by the protein expression of other subunits. Protein levels of NSE, a marker that specifically recognizes neurons, were assessed to determine whether the number of neurons was similar in autism and control samples. Western blotting demonstrated that the amount of NSE protein was similar in both clinical groups (see figure 3A) .
Because there was a significant increase in both GluR1 and EAAT 1 proteins in autism, Western blotting was used to determine whether there were differences in the protein amounts of additional glutamate-related genes in the same cerebellum samples. There was an increase in the protein of EAAT 2 and the NMDA receptor 1 in autism (p Ͻ 0.04 and p Ͻ 0.05; see figure 3B ). Conversely, no significant differences were detected in the protein levels of glutamate decarboxylase 1/2, metabotropic 2/3 receptors, or AMPA 2/3 glutamate receptors (data not shown).
Protein levels of band 4.1N, which was identified by subtractive hybridization, and other glutamate receptor binding proteins were also assessed in the same cerebellum samples. Band 4.1N protein was increased in autism cerebellum (p Ͻ 0.05; see figure 3B ). The C termini of AMPA receptors have also been shown to interact with GRIP. 23 GRIP protein was increased in samples from subjects with autism (p Ͻ 0.04) when compared with control samples. However, PSD-95, a protein that associates with the C termini of the NMDA receptor subunits, 24 was not significantly different in autism cerebellum (data not shown). Multiple regression analysis demonstrated that none of the significant protein differences between autism and control groups were a function of age or PMI. Several other genes involved in synaptic transmission were examined by Western blotting. There was no significant difference in GABA A receptor ␤ subunit, glutamate decarboxylase 1/2, purinergic receptor P2X 7, or dopamine receptor 2 protein amount between control and autistic cases (data not shown).
Glutamate receptor autoradiography. The density of NMDA-and AMPA-type glutamate receptors was examined by receptor autoradiography, due to the mRNA and protein abnormalities detected by Western blotting, RT-PCR, and microarray analysis. Glutamate receptor density was evaluated in the cerebellum of six subjects with autism and nine control subjects. AMPA glutamate receptor density was decreased in both the granule cell layer (p Ͻ 0.05) and molecular cell layer (p Ͻ 0.01) of the autism cerebellum ( figure 4A ). Multiple regression analysis demonstrated that these receptor density differences between autism and control groups were not a function of age or PMI. Unlike AMPA receptor density, NMDA receptor density in these regions did not differ significantly between control and autism groups. Figure 4B shows NMDA and AMPA receptor density in representative autism and control cerebellum sections. The prefrontal cortex (four autistic versus seven control cases) and caudate-putamen (three autistic versus six control cases) were also assessed for differences in AMPA or NMDA receptor density; however, no significant differences were detected (see figure 4A ).
Discussion. Several biochemical differences have been reported in biologic samples from subjects with autism, yet few, if any, of these studies examined postmortem brains. The study of the brains of individuals with autism is important because autism is considered a neurodevelopmental disorder and pathology in several regions is known to exist. The study of postmortem human brain, however, presents unique experimental challenges. 12 As we are examining postmortem samples long after the onset of the disorder, it is more likely that we are identifying secondary consequences of the disorder. However, at this time no animal model exists that can be used to study the developmental biology of autism. In addition, the quality of RNA isolated from postmortem brain may be variable and can depend on the agonal state (i.e., the events preceding death, such as hypoxia or other trauma to the brain) and the PMI. 25 The quality of RNA may be predicted from the pH of the brain, 19 and in the present study the pH of samples was consistent and within an acceptable range. We also confirmed the integrity of RNA by gel electrophoresis and absorbance measurements. Multiple regression analysis demonstrated that no mRNA or protein differences between the two groups were attributed to PMI. Previous studies indicate that glutamate receptors remain stable for postmortem and storage intervals that were similar to ours. 26 Autism is a heterogeneous disorder and it is therefore important to take into consideration clinical variations such as IQ and the presence of seizures. Because glutamate plays a role in the initiation and propagation of seizures, we sought to correlate significant glutamate differences detected in this study to subjects with a history of seizures. Four of the 10 subjects with autism were affected by seizures; however, we detected no significant correlation between these cases and the magnitude of mRNA or protein changes. A majority of the prefrontal cortex and caudate-putamen samples from the autism group examined by autoradiography, however, were from subjects who had seizures, making this correlation difficult. It is likely that the heterogeneity of these samples obscured the identification of additional genes that are abnormally regulated in autism. In addition, several of the patients were taking medications, some of which could potentially affect gene expression in brain.
cDNA microarray analysis provided several directions for autism research by identifying molecules that have never been associated with autism. GFAP and clusterin mRNA were significantly increased in the cerebellum samples from subjects with autism in both RT-PCR and microarray experiments. Increased mRNA levels of clusterin are seen in a variety of disorders, such as AD; however, its physiologic function is unknown. 27 One study found that protein levels of GFAP in CSF were almost three times higher in a group of 47 individuals with autism compared with similarly aged normal individuals. 28 In addition, a significant increase in the incidence of GFAP autoantibodies was found in the plasma of 53 subjects with autism compared with 58 controls. 29 GFAP, a biochemical marker of astrocytes, increases during astroglial activation. 30 If the increase in GFAP mRNA we detected in autism is indicative of an increase in GFAP protein, it is possible that reactive gliosis may contribute to autism pathophysiology. The few studies that have examined postmortem brain from subjects with autism have not identified gliosis or an increase in GFAP protein 5 ; however, it may be mild or restricted to certain areas of the brain. Additional pathologic studies examining a greater number of cases and a variety of regions are therefore needed. Several autism susceptibility loci have been identified by genome-wide screens 21 and many chromosomal aberrations have been linked with autism. 31 A few genes that were within these regions were found to be up-or downregulated in autism in our analyses, including an EST (GenBank identifier AA946611), GABA A receptor ␣5 subunit, and glycoprotein M6b.
cDNA microarray analysis also led to the identification of glutamate abnormalities in the cerebellum of individuals with autism. Abnormalities in serotonin, dopamine, norepinephrine, opiates, and several other neurotransmitters have been reported in autism. 32 The potential pathophysiologic role of glutamate, the most abundant excitatory neurotransmitter in the brain, has not been explored to the same extent. There are several reasons that a glutamate hypothesis of autism is attractive. Receptors for glutamate are especially concentrated in regions that have been repeatedly implicated in autism, including the cerebellum and hippocampus. 33, 5 In addition, autism is believed to be a developmental disorder of the brain and during development glutamate plays a crucial role in the formation of brain cytoarchitecture by regulating processes such as neuronal outgrowth and synaptogenesis. 34 The distribution, electrophysiology, and molecular characteristics of glutamate receptors change markedly during this period, making the formation of the brain vulnerable to aberrations in glutamate neurotransmission. 34 In the adult brain, the NMDA-type glutamate receptor is required for long-term potentiation, the physiologic process underlying learning and memory. 35 It has been speculated that at least some of the behavioral abnormalities of autism can be attributed to a memory deficit. 36 Further, a study demonstrated that glutamate may be important in the acquisition of emotional behavior. 37 Disrupted glutamate transmission could therefore account for a constellation of the cognitive deficits in autism. Finally, symptoms elicited by glutamate receptor antagonist treatment, such as extreme focus on trivial details and heightened or distorted pain perception, are similar to symptoms of autism. 38 Blockade of glutamate receptors may also improve autistic symptoms. 39, 40 Receptor autoradiography demonstrated that AMPA receptor density was significantly decreased in the cerebellum of subjects with autism. Expression of these receptors could be decreased for a variety reasons, including inefficient aggregation and immobilization in the synapse or a decrease in the number of cell types that express AMPA receptors. Interactions with several proteins, including GRIP and band 4.1N, are thought to be important for the localization and synaptic expression of AMPA receptors on the cell surface. 23 For instance, disruption of the interaction between GluR1 and band 4.1N in cultured cells has been shown to reduce the level of surface AMPA receptors. 22 In this study, Western blotting demonstrated that GRIP protein was significantly increased in postmortem autism cerebellum. We also showed that the mRNA and protein levels of band 4.1N were expressed at abnormally high levels in autism. Thus, abnormalities in the proteins that are responsible for glutamate receptor synaptic localization, clustering, or immobilization, such as band 4.1 or GRIP, may be the reason for reduced expression of AMPA-type glutamate receptors. Although autoradiography determined there was a decrease in AMPA receptors, Western blotting indicated an increase in the AMPA 1 glutamate receptor in total brain homogenate. The explanation for this discrepancy is unknown; however, the ligands used in the receptor density experiments broadly recognized all types of AMPA receptors. Kinetic analyses of glutamate receptor binding may help to address this issue.
In addition to the abnormalities detected in the AMPA receptors, both the mRNA and protein levels of EAAT 1 and 2 were significantly increased in autism cerebellum. EAAT 1 and EAAT 2 are predominantly located on astroglia and their main function is to remove glutamate from the extrasynaptic space. 41 Studies have shown that the protein level and activity of glutamate transporters are controlled by the extracellular glutamate concentration or by activity-dependent mechanisms. 42 This suggests that increased EAAT 1 and 2 protein levels in the autism group may be due to above-normal extracellular glutamate concentrations. In fact, cultured astrocytes exposed to glutamate for prolonged periods acquire an increased capacity for glutamate uptake and increased expression of EAAT 1 protein. 43 Because many neurons in the cerebellum use glutamate as a neurotransmitter, and the glutamate transporters are the only mechanism to reduce concentrations of extracellular glutamate, aberrations in their functioning may have severe pathologic effects such as excitotoxicity. 44 Alternatively, the increase in EAAT 1 and 2 protein could be explained by an increased level of glutamate transmission or innervation in neurons, requiring increased expression of glutamate transporters. Currently, there is no pathologic evidence in autism to support this theory.
Pathologic studies of postmortem cerebellum of autistic persons have shown variable reductions in the number of Purkinje cells. [5] [6] [7] The increased representation of molecules expressed on the remaining cells such as glia could therefore have resulted in increased EAAT 1 and EAAT 2 protein. Microarray analysis of gene expression in autism cerebellum, however, did not detect significantly decreased expression of neuron-specific markers. In addition, Western blotting of postmortem cerebellum homogenates demonstrated that the neuronal marker NSE was unchanged in autism. Because the glutamate system is involved in the development of brain cytoarchitecture, aberrations in the system during development may have disrupted synaptic connections or the formation of certain cell types. 34 This, in turn, may have affected the numbers and distribution of glutamate receptors and glutamate transporters in the brain of persons with autism. Additional pathologic studies of postmortem brain from individuals with autism confirming Purkinje cell loss and describing more fully abnormalities in cytoarchitecture would be extremely informative. In the future, it may also be interesting to assess the expression of AMPA receptors and glutamate transporters in additional brain regions with known pathology and at younger ages, if postmortem tissue were available.
Additional research into the glutamatergic system in autism is warranted as it may provide a rationale for treatment. Clinical observations suggest that ketamine anesthesia, which specifically blocks NMDA receptors, has beneficial effects (calming, focused attention) on children with autism. 40 However, more must be known about the nature of the glutamate system's involvement in the pathogenesis of autism in order to justify clinical research in this area. This is especially true because both increased and decreased levels of glutamate have been shown to be detrimental in the developing brain. Because autism is currently diagnosed solely on the basis of clinical manifestations, additional neurochemical research will be useful in identifying markers for the disorder or in identifying more homogeneous subgroups. For a study of this nature, it would be crucial to obtain a large number of quality postmortem brain samples, allowing for glutamatergic disturbances in each patient to be compared in multiple brain regions across experiments.
